Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2Porter's Five Force Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1. Drivers
4.1.1 Models on Next-Gen Business
4.1.2 High growth in the prevalence of chronic diseases
4.1.3 Less cost biosimilar drugs
4.2 Restraints
4.2.1 High initial investment in research
4.2.2 Complexity in production
4.3 Opportunities
4.3.1 Emerging from biosimilar drugs
4.4 Challenges
4.4.1. Low cost compared to original products
Chapter 5 Asia Pacific Biosimilar Market – By Product
5.1 Insulin
5.2 Interferon
5.3 Human Growth Hormone
5.4 Granulocyte colony-stimulating factor
5.5 Others
Chapter 6 Asia Pacific Biosimilar Market - By Services
6.1 Clinical trials
6.2 Contract research & manufacturing services
Chapter 7 Asia Pacific Biosimilar Market - By Technology
7.1. Chromatography
7.2 Recombinant DNA Technology
7.3 Monoclonal Antibodies Technology
7.4 Nuclear magnetic resonance Technology
7.5 Others
Chapter 8 Asia Pacific Biosimilar Market - By Application
8.1 Oncology diseases
8.2 Chronic and autoimmune diseases
8.3 Blood disorders
8.4 Growth hormone deficiency
8.5 Others
Chapter 9 Asia Pacific Biosimilar Market - By Geography
9.1 Introduction
9.2 Asia Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia & New Zealand
9.2.6. Rest of APAC
Chapter 10 Asia Pacific Biosimilar Market - Company Profiles
10.1. LG Life Sciences Limited
10.2. Teva Pharmaceuticals
10.3. Celltrion
10.4. Hospira
10.5. Accord Healthcare
10.6. Hexal
10.7. Zydus Cadila Healthcare
10.8. Novartis/Sandoz
10.9. Apotex
10.10. Samsung Bioepis
10.11. Mylan
10.12. Eli Lilly
10.13. Harvest Moon Pharmaceuticals
10.14. Biocon
10.15. Bioxpress Therapeutics
Chapter 11 Asia Pacific Biosimilar Market - Competitive Landscape
11.1. Market Share Analysis
11.2. Strategies Adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
Chapter 12 Market Insights
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
Chapter 13 Appendix
13.1 List of Tables
13.2 List of Figures
